Cellink focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. CELLINK’s innovative and patent pending bioink is a biomaterial innovation that enables human cells to grow and thrive such as they would in the natural human body environment. Today, the company’s disruptive technology platform is being utilized to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments. The company has, within 12 months, been able to commercialize products in more than 40 countries and sold to more than hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and FDA. Follow us on our journey to change the world of medicine.
Cellink has 26 different types of inks for tissue-specific usage.
One of them is CELLINK® FIBRINOGEN. It has been developed as a bioink for application with cells that require fibrinogen or are developed to recapitulate the native wound healing environment. Fibrinogen is a critical protein that is found in the healing of many tissues due to its role in clots. This bioink retains the excellent printability and ease of cross-linking found with the universal CELLINK® bioink.
They have been able to create many liquid substrate that can be used to allow the printing of different cells. It is a liquid scaffold.
Multiple inks can be placed in the printing systems.
With the bioinks they will be able to leverage the vast inkjet printing technology and systems to scale to faster and larger applications. They will need to certify, validate and modify inkjet systems for bioink.
Cellink currently has 55 people.
They had one of the fastest IPOs and they have rapidly become profitable supply bioinks for pharma testing applications. Replacing rabbits and skin patches for product and drug testing.
The current device has 3 heads and temperature controls. Different tissues need cooling or heating and printheads can be swapped out.
They are profitably validating and scaling their technology.
They are ISO and CMART certified.
They will be able scale to larger and larger tissue sizes. Larger and larger machines.
They can scale to industrial vats and factory scale systems.
They will move from Pharma testing to animal tissue and organ applications and animal healthcare to human.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.